866-997-4948(US-Canada Toll Free)

Trerief Analysis and Estimates from 2009 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 25 Pages


GlobalDatas pharmaceuticals report, Trerief Analysis and Estimates from 2009 to 2020 provides Trerief sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope
  • Therapy area profile including patient population for the Japan (seven major markets)
  • Analysis and review of Trerief including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Trerief including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Trerief in the Japan
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Parkinsons Disease 4
2.2 Symptoms of Parkinsons Disease 4
2.3 Diagnosis of Parkinsons Disease 5
2.4 Parkinsons Disease Treatment Strategies 5
2.5 Parkinsons Disease Market 6
2.6 Epidemiology 6
2.7 Parkinsons Disease by Age and Gender 6
2.8 Etiology 7
2.9 GlobalData Report Guidance 7

3 Parkinsons Disease: Market Characterization 8
3.1 Parkinsons Disease Market 8
3.2 Parkinsons Disease Market Forecasts and CAGR 8
3.3 Factors Affecting Parkinsons Disease Market 9
3.3.1 High Prevalence: Parkinsons Disease is the Second Most Frequent Neurodegenerative Disorder 9
3.3.2 Increase in Old Age Population 9
3.3.3 Patent Expiry of Prominent Drugs 9

4 Stages of Parkinsons Disease and Comparison of Treatments 10
4.1 The Hoehn and Yahr Scale 10
4.2 Modified Hoehn and Yahr Scale 10
4.3 The UPDRS 11

5 Staging of Parkinsons Disease 14
5.1 Distribution of Parkinsons Disease Patients by Age Groups 14
5.2 Distribution of Patients by Stages 14

6 Trerief 15
6.1 Introduction 15
6.2 Mechanism of Action 15
6.3 Clinical Studies 15
6.4 Approval History of Trerief 16
6.5 Factors Affecting Sales of Trerief 16
6.5.1 Absence of Trerief in the US and EU Market 16
6.5.2 Only Drug for Second Line Therapy of Parkinsons Disease 16
6.5.3 Unmet Medical Need 16
6.6 Drug Evaluation 16
6.6.1 Drug Risk Benefit Score 16
6.6.2 Intensity of Competition 17
6.7 Sales Estimates 18
6.7.1 Target Patient Pool for Parkinsons disease 18
6.7.2 Dosing 18
6.7.3 Market Penetration 19
6.7.4 Annual Cost of Therapy 19
6.7.5 Sales Estimates of Trerief in Japan 20

7 Parkinson Disease Market: Appendix 21
7.1 Market Definitions 21
7.2 List of Abberiviations 21
7.3 Research Methodology 21
7.3.1 Coverage 21
7.3.2 Secondary Research 21
7.3.3 Forecasting 22
7.3.4 Number of Patients Approved to take the Drug 22
7.3.5 Net Penetration of Drug 22
7.3.6 Net Annual Dosing 23
7.3.7 Annual Cost of Therapy 23
7.3.8 Primary Research 23
7.3.9 Expert Panels 24
7.4 Drug Sales Estimates Model 24
7.5 Contact Us 24
7.6 Disclaimer 25
7.7 Sources 25

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 4
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 4: Four Items, Part 1 of UPDRS 11
Table 5: Thirteen Items, Part 2 of UPDRS 11
Table 6: Fourteen Items, Part 3 of UPDRS 12
Table 7: Fourteen Items, Part 3 of UPDRS 12
Table 8: Distribution of Parkinsons Patients According to Hoehn and Yahr Classification 14
Table 9: Change in UPDRS Part III from Baseline in Phase III Clinical Trials 15
Table 10: Approval History of Trerief 16
Table 11: Drug Risk Benefit Score of Trerief 17
Table 12: Summary of Adverse Events 17
Table 13: Annual Cost of Trerief for Parkinsons Disease, 2010 19
Table 14: Trerief, Parkinsons Disease, Japan, Sales Estimates ($m), 2009-2020 20

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons Disease and Their Potential Sites of Action in the CNS 5
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 6
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 8
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 9
Figure 5: Points Distribution of UPDRS 13
Figure 6: Distribution of Parkinsons Disease Patients by Hoehn & Yahr Classification 14
Figure 7: Drug Model Diagram of Trerief 18
Figure 8: Trerief, Parkinsons Disease, Japan, Sales Estimates ($m), 2009-2020 20
Figure 9: Drug Model Diagram 23
Figure 10: Patients Approved for the Drug 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *